Home » Stocks » uniQure

uniQure N.V. (QURE)

Stock Price: $42.21 USD -0.04 (-0.09%)
Updated Aug 5, 2020 12:45 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.88B
Revenue (ttm) 5.31M
Net Income (ttm) -135.58M
Shares Out 44.45M
EPS (ttm) -3.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 5, 2020
Last Price $42.21
Previous Close $42.25
Change ($) -0.04
Change (%) -0.09%
Day's Open 42.35
Day's Range 41.81 - 42.85
Day's Volume 146,356
52-Week Range 36.20 - 76.69

More Stats

Market Cap 1.88B
Enterprise Value 1.63B
Earnings Date (est) Nov 3, 2020
Ex-Dividend Date n/a
Shares Outstanding 44.45M
Float 34.41M
EPS (basic) -3.14
EPS (diluted) -3.13
FCF / Share -2.65
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.71M
Short Ratio 3.84
Short % of Float 9.40%
Beta 1.23
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 353.31
PB Ratio 5.91
Revenue 5.31M
Operating Income -139.51M
Net Income -135.58M
Free Cash Flow -117.58M
Net Cash 243.12M
Net Cash / Share 5.47
Gross Margin -1,647.01%
Operating Margin -2,627.33%
Profit Margin -2,553.30%
FCF Margin -2,214.35%
ROA -26.82%
ROE -68.21%
ROIC -123.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (16)

Buy 11
Overweight 2
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$73.50*
(74.13% upside)
Low
56.0
Current: $42.21
High
91.0
Target: 73.50
*Average 12-month price target from 14 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue7.2811.2813.1125.1010.586.14
Revenue Growth-35.48%-13.91%-47.78%137.27%72.25%-
Gross Profit7.2811.2813.1125.1010.586.14
Operating Income-123-90.38-86.77-73.41-71.93-54.70
Net Income-124-83.30-79.26-73.37-82.08-49.78
Shares Outstanding40.0035.6426.9825.0422.0817.12
Earnings Per Share-3.11-2.34-2.94-2.93-3.72-2.91
Operating Cash Flow-98.68-76.04-64.27-72.197.47-36.85
Capital Expenditures-5.65-2.38-4.46-15.29-7.61-22.20
Free Cash Flow-104-78.42-68.73-87.48-0.14-59.05
Cash & Equivalents3782351591322220.00
Total Debt73.0635.4720.7920.2420.21-
Net Cash / Debt3051991391122010.00
Assets449274210190263-
Liabilities12694.30120127135-
Book Value32318089.3663.63128-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name uniQure N.V.
Country Netherlands
Employees 248
CEO Matthew C. Kapusta

Stock Information

Ticker Symbol QURE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: QURE
IPO Date June 20, 2007

Description

uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.